# Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma

> **NCT00443976** · PHASE1 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 35 (actual)

## Conditions studied

- Non-Hodgkins Lymphoma
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** Aurora kinase inhibitor AT9283

## Key facts

- **NCT ID:** NCT00443976
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01-30
- **Primary completion:** 2010-04-09
- **Final completion:** 2012-01-06
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2023-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00443976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00443976, "Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00443976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*